Search clinical trials for: Thymic Shielding

Total 178 results

Samsung Medical Center

Recruiting

neoadjuvant_thymic Epithelial Tumor

Thymic Epithelial Tumor

Korea, Republic of
VM Oncology, LLC

Recruiting

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sarcoma | Cervical Cancer | Breast Cancer | Adenoid Cystic Carcinoma | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Thymic Carcinoma | Lung Cancer | Mesothelioma | Bladder Cancer | Head and Neck Carcinoma | Any Solid Tumors Progressed After a Prior Immunotherapy

United States, Puerto Rico
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) (Style)

Thymic Carcinoma | Type B3 Thymoma

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Stage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Thymic Carcinoma | Thymoma

United States
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

French National Observatory of Patients With Thymic Epithelial Tumor (RYTHMIC)

Thymic Epithelial Tumor

France
Fudan University

Recruiting

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Thymoma and Thymic Carcinoma

China
National Cancer Institute (NCI)

Recruiting

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Extrapulmonary Small Cell Cancer | Pulmonary Neuroendocrine Tumors | Thymic Epithelial Tumors

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Anaplastic Large Cell Lymphoma | Small Lymphocytic Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin Lymphoma | Enteropathy-Associated... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Transformed... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Unresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic Carcinoma

United States
University of Washington
Genentech, Inc.

Suspended

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich... and other conditions

United States
Weill Medical College of Cornell University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

Thymic Carcinoma

United States
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell Lung | Carcinoma, Thymic

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
MedSIR
Merck Sharp & Dohme LLC

Active, not recruiting

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)

Metastatic Thymic Carcinoma | Thymoma Type B3

Spain, France, Italy
Hoffmann-La Roche

Active, not recruiting

A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Carcinoma, Thymic

China
Vanderbilt-Ingram Cancer Center
Bristol-Myers Squibb; Xcovery Holdings, Inc.

Active, not recruiting

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Thymic Carcinoma | Non-small Cell Lung Cancer | Small-Cell Lung Cancer | Refractory Thoracic Tumors

United States
Dwight Owen
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Thymic Carcinoma

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Thymic Carcinoma

China
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (DA-EPOCH-R)

Diffuse Large B Cell Lymphoma | Post Transplant Lymphoproliferative Disorder | Primary Mediastinal (Thymic) Large B-cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Classic Hodgkin Lymphoma | Refractory... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Refractory Primary Mediastinal (Thymic)... and other conditions

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Cancer

United States, Canada
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Completed

Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Recurrent Lung Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Caregiver | Metastatic Thymic Carcinoma | Malignant Pleural... and other conditions

United States
University of California, San Francisco

Completed

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Plasma Cell Myeloma | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin... and other conditions

United States
Stanford University

Enrolling by invitation

Molecular Analysis of Thoracic Malignancies

Carcinoma, Non-Small-Cell Lung | Thymic Carcinoma | Thymoma | Lung Cancer | Mesothelioma | Thymus Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma

Thymic Carcinoma | Thymoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

Thymoma and Thymic Carcinoma

United States, South Africa
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Eli Lilly and Company; City of Hope National Medical...

Active, not recruiting

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Thymic Carcinoma | Thymoma | Clinical Masaoka Stage II to IVA

United States
Cairo University

Completed

Evaluation of Immediate Implant Placement In The Esthetic Zone Using the Bone Shielding Concept Versus Dual Zone Therapy

Alveolar Bone Loss | Immediate Implants | Esthetic Zone | Dual Zone Technique | the Bone Shielding Concept

Egypt
St. Joseph's Hospital and Medical Center, Phoenix
Arizona Commerce Commission, Phoenix AZ; GT Medical Technologies, Inc.

Completed

Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device

Central Nervous System Lesion

United States
European Organisation for Research and Treatment...
ETOP IBCSG Partners Foundation

Active, not recruiting

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM)

Thymic Carcinoma | Thymoma Type B3

Netherlands, Spain, France, Belgium, United Kingdom, Switzerland
Georgetown University
Hackensack Meridian Health; Karyopharm Therapeutics Inc

Terminated

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy (SELECT)

Thymoma | Advanced Thymic Epithelial Tumor

United States
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
Fred Hutchinson Cancer Center
ADC Therapeutics

Withdrawn

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent High... and other conditions

United States
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Thymic Carcinoma | Thymoma | Non-small Cell Lung Carcinoma | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Cholangiocarcinoma | Breast Carcinoma | Fallopian Tube Carcinoma and other conditions

United States
St. Justine's Hospital

Completed

Complete Shielding of Multivitamins to Reduce Toxic Peroxides in the Parenteral Nutrition: A Pilot Study (C-SMART-PN)

Pathologic Processes | Lung Diseases | Infant, Premature, Diseases | Bronchopulmonary Dysplasia | Infant, Newborn, Disease | Parenteral Nutrition | Respiratory Tract Disease

Canada
University of Maryland, Baltimore

Terminated

Cardiac MRI Biomarker Testing (GCC 1618)

Breast Cancer | Mesothelioma | Thoracic Cancer | Thymic Cancer | Lung Cancer (Non-Small Cell)

United States
Armando Santoro, MD

Completed

Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy (ONC-2010-001)

Thymoma and Thymic Carcinoma

Italy
Istituto Clinico Humanitas

Completed

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy (RESOUND)

Melanoma | Sarcoma | Ovarian Cancer | Thymic Carcinoma | Pancreas Cancer | Thymoma Type B3 | Thymoma Type B2

Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Suspended

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | CD20 Positive | Aggressive Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Unclassifiable | Intravascular Large B-Cell Lymphoma | T-Cell/Histiocyte-Rich...

United States

Search clinical trials for: Thymic Shielding

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations